Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Cells · 12.01.2024 · 13 (2) · 146
DOI: 10.3390/cells13020146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.01.2024. Verfasst von Caroline Lonez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Celyad Oncology SA, 1435 Mont-Saint-Guibert, Belgium. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations. However, several limitations remain, including those associated with the time-consuming and highly personalized manufacturing of autologous CAR-Ts. Technologies to establish “off-the-shelf” allogeneic CAR-Ts with low alloreactivity are currently being developed, with a strong focus on gene-editing technologies. Although these technologies have many advantages, they have also strong limitations, including double-strand breaks in the DNA with multiple associated safety risks as well as the lack of modulation. As an alternative, non-gene-editing technologies provide an interesting approach to support the development of allogeneic CAR-Ts in the future, with possibilities of fine-tuning gene expression and easy development. Here, we will review the different ways allogeneic CAR-Ts can be manufactured and discuss which technologies are currently used. The biggest hurdles for successful therapy of allogeneic CAR-Ts will be summarized, and finally, an overview of the current clinical evidence for allogeneic CAR-Ts in comparison to its autologous counterpart will be given.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Celyad Oncology SA, 1435 Mont-Saint-Guibert, Belgium.
ORCID-Profile: Caroline Lonez, Eytan Breman
Zitieren
APA
Lonez, C., & Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13(2), 146. https://doi.org/10.3390/cells13020146
Vancouver
Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells. 2024;13(2):146. doi:10.3390/cells13020146
BibTeX
@article{Lonez2024,
author = {Lonez, Caroline and Breman, Eytan},
title = {Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?},
journal = {Cells},
year = {2024},
volume = {13},
number = {2},
pages = {146},
doi = {10.3390/cells13020146}
}
EUVIMED